13F Portfolios

Exome Asset Management LLC — IONIS PHARMACEUTICALS INC. IONS: Quarterly 13F Position History

Exome Asset Management LLC has reported IONIS PHARMACEUTICALS INC. (IONS) on 6 13F-HR filings in Pactolio's tracked window, first appearing in Q4 2024. As of Q1 2026, the position is sized at 110,064 shares ($8.3M market value, 4.86% of the equity book). Quarter-over-quarter share count change: 6,451 (-5.5%) .

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 6 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 110,064 6,451 -5.5% $8.3M 4.86% $75.09
Q4 2025 116,515 14,501 -11.1% $9.2M 4.55% $79.11
Q3 2025 131,016 +9,900 +8.2% $8.6M 5.66% $65.42
Q2 2025 121,116 14,500 -10.7% $4.8M 3.93% $39.51
Q1 2025 135,616 +74,249 +121.0% $4.1M 3.66% $30.17
Q4 2024 61,367 $2.1M 1.61% $34.96

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Exome Asset Management LLC first disclose a IONS position in 13F-HR filings?

Exome Asset Management LLC first reported IONIS PHARMACEUTICALS INC. (IONS) on its 13F-HR filing for the period ending 2024-12-31 (Q4 2024). The position has appeared on 6 reported quarters within Pactolio's tracked window.

What was Exome Asset Management LLC's most recent quarter-over-quarter share-count change in IONS?

Between Q4 2025 and Q1 2026, Exome Asset Management LLC reduced its IONS position by 6,451 shares (-5.5%), leaving 110,064 shares at a market value of $8.3M.

Does the implied price-per-share represent Exome Asset Management LLC's cost basis in IONS?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.